Literature DB >> 26831184

Haematological cancer: Ponatinib in CML - keeping PACE with multiple mutations.

Peter Sidaway.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26831184     DOI： 10.1038/nrclinonc.2016.13

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.

Authors:  Wendy T Parker; David T O Yeung; Alexandra L Yeoman; Haley K Altamura; Bronte A Jamison; Chani R Field; J Graeme Hodgson; Stephanie Lustgarten; Victor M Rivera; Timothy P Hughes; Susan Branford
Journal:  Blood       Date:  2016-01-14       Impact factor: 22.113
  1 in total
  1 in total

1.  Arresting of miR-186 and releasing of H19 by DDX43 facilitate tumorigenesis and CML progression.

Authors:  J Lin; J-C Ma; J Yang; J-Y Yin; X-X Chen; H Guo; X-M Wen; T-J Zhang; W Qian; J Qian; Z-Q Deng
Journal:  Oncogene       Date:  2018-02-16       Impact factor: 9.867
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.